OR (95% CI) | |
NLR, continuous variable | |
Entire study population | 1.48 (1.21–1.81) |
No AECOPD previous year | 1.23 (0.88–1.72) |
≥1 AECOPD previous year | 1.64 (1.14–2.36) |
NLR ≥3.00 versus <3.00 | |
Entire study population | 1.61 (0.91–2.84) |
No AECOPD previous year | 0.89 (0.36–2.22) |
≥1 AECOPD previous year | 2.88 (1.00–8.25) |
B-Eos, continuous variable# | |
Entire study population | 1.02 (0.86–1.19) |
No AECOPD previous year | 1.10 (0.87–1.37) |
≥1 AECOPD previous year | 0.96 (0.72–1.28) |
B-Eos ≥300 versus <300 cells·µL−1 | |
Entire study population | 1.47 (0.83–2.63) |
No AECOPD previous year | 2.10 (0.84–5.15) |
≥1 AECOPD previous year | 1.15 (0.40–3.28) |
Models were calculated for the entire study population, and for observations where the subjects had and had not had an acute exacerbation the previous year, respectively. Each row represents a separate model. NLR: blood neutrophil-to-lymphocyte ratio; AECOPD: acute exacerbation of COPD; B-Eos: blood eosinophils. #: per 100 cells·µL−1 increase.